Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Your provider collaborates with you to choose the best treatment based on medical assessments, insurance coverage, and personal preferences
The FLOW trial demonstrated a 24% reduction in kidney disease progression in patients with type 2 diabetes and chronic kidney disease taking semaglutide
The protocol: Reduce sulfonylurea dose by 50% when starting semaglutide Monitor blood glucose before meals and at bedtime for 2 weeks Many patients discontinue sulfonylureas entirely within 4 to 8 weeks as semaglutide reaches therapeutic levels The SUSTAIN-2 trial (Ahrn et al., Diabetes Care , 2018) showed that 41% of patients on sulfonylureas plus semaglutide experienced hypoglycemia, compared to 11% on semaglutide alone
doi: 10.7150/ijbs.59965 11
US$ 20.96
US$ 20.42
US$ 29.54
US$ 28.74
US$ 24.69
US$ 21.87
US$ 20.43
